113 related articles for article (PubMed ID: 12217751)
1. No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.
Paskeviciute L; Roed H; Engelholm S
Gynecol Oncol; 2002 Sep; 86(3):297-301. PubMed ID: 12217751
[TBL] [Abstract][Full Text] [Related]
2. No rules without exception: a long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.
Paskeviciute L; Roed H; Engelholm A
Eur J Cancer; 2002 Nov; 38 Suppl 6():S73. PubMed ID: 12409084
[No Abstract] [Full Text] [Related]
3. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
4. Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer.
Marinaccio M; D'Addario V; Serratì A; Pinto V; Cagnazzo G
Eur J Gynaecol Oncol; 1996; 17(4):286-8. PubMed ID: 8856307
[TBL] [Abstract][Full Text] [Related]
5. Primary and salvage therapy with LH-RH analogues in ovarian cancer.
Emons G; Schulz KD
Recent Results Cancer Res; 2000; 153():83-94. PubMed ID: 10626291
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
7. Second-line therapy of advanced ovarian cancer with GnRH analogs.
Balbi G; Piano LD; Cardone A; Cirelli G
Int J Gynecol Cancer; 2004; 14(5):799-803. PubMed ID: 15361187
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
du BA; Meier W; Lück HJ; Emon G; Moebus V; Schroeder W; Costa S; Bauknecht T; Olbricht S; Jackisch C; Richter B; Wagner U
Ann Oncol; 2002 Feb; 13(2):251-7. PubMed ID: 11886002
[TBL] [Abstract][Full Text] [Related]
9. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
12. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
13. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
Akaza H; Homma Y; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Ohashi Y; Aso Y
Jpn J Clin Oncol; 2000 Mar; 30(3):131-6. PubMed ID: 10798540
[TBL] [Abstract][Full Text] [Related]
14. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Oefelein MG; Cornum R
J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.
Bruzzone M; Catsafados E; Miglietta L; Amoroso D; Pedulla F; Giannessi PG; Locatelli MC; D'Antona A; Foglia G; Mammoliti S; Turno F; Gentile A; Nicosia F; Luporini G; Ragni N; Boccardo F
Oncology; 1996; 53(5):349-53. PubMed ID: 8784466
[TBL] [Abstract][Full Text] [Related]
16. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.
Zidan J; Zohar S; Mijiritzky I; Kral S; Bilenca B
Isr Med Assoc J; 2002 Aug; 4(8):597-9. PubMed ID: 12183859
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
18. Long-term suppression of testosterone after treatment with a gonadotropin-releasing hormone agonist in a woman with a presumed testosterone secreting ovarian tumor.
Barnes RB; Ehrmann DA
J Clin Endocrinol Metab; 1997 Jun; 82(6):1746-8. PubMed ID: 9177374
[No Abstract] [Full Text] [Related]
19. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
Emons G; Ortmann O; Teichert HM; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
Cancer; 1996 Oct; 78(7):1452-60. PubMed ID: 8839551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
